Akebia Therapeutics
(AKBA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 51,870 | 42,925 | 90,466 | 149,800 | 228,698 |
| Receivables | 34,368 | 39,290 | 40,284 | 51,581 | 66,845 |
| Inventories | 16,243 | 15,691 | 21,568 | 36,628 | 61,017 |
| TOTAL | $113,831 | $118,149 | $185,182 | $271,149 | $371,437 |
| Non-Current Assets | |||||
| PPE Net | 2,200 | 3,629 | 5,214 | 6,754 | 8,622 |
| Intangibles | 59,044 | 95,086 | 131,128 | 167,171 | 199,223 |
| Other Non-Current Assets | 45,595 | 24,839 | 34,530 | 84,273 | 64,857 |
| TOTAL | $106,839 | $123,554 | $170,872 | $258,198 | $272,702 |
| Total Assets | $220,670 | $241,703 | $356,054 | $529,347 | $644,139 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 17,500 | 32,000 | 97,543 | 0 |
| Accounts payable and accrued liabilities | 15,180 | 14,635 | 18,021 | 33,588 | 41,308 |
| Accrued Expenses | 63,460 | 67,735 | 75,777 | 109,014 | 130,624 |
| Other current liabilities | 2,274 | N/A | N/A | N/A | N/A |
| TOTAL | $80,914 | $99,870 | $129,536 | $261,051 | $187,146 |
| Non-Current Liabilities | |||||
| Long Term Debt | 38,693 | 17,183 | 34,078 | 0 | 96,378 |
| Deferred Revenues | N/A | N/A | 3,738 | 20,906 | 15,214 |
| Other Non-Current Liabilities | 150,248 | 111,938 | 143,914 | 172,814 | 87,652 |
| TOTAL | $188,941 | $172,417 | $221,288 | $194,288 | $209,375 |
| Total Liabilities | $269,855 | $272,287 | $350,824 | $455,339 | $396,521 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 236,231 | 209,372 | 184,248 | 181,231 | 153,502 |
| Common Shares | 2 | 2 | 2 | 1 | 1 |
| Retained earnings | -1,678,360 | -1,608,950 | -1,557,025 | -1,462,799 | -1,177,511 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 13 |
| TOTAL | $-49,185 | $-30,584 | $5,230 | $74,008 | $247,618 |
| Total Liabilities And Equity | $220,670 | $241,703 | $356,054 | $529,347 | $644,139 |